
New ZEALAND'S Medicines Landscape 2022/23

Medicines New Zealand Where is New Zealand in this race? New Zealand lags behind other OECD nations for access to modern medicines

Percentage of New Medicines Reimbursed by Public Insurance Plans by OECD Country (of all 460 new medicines launched from 2012 to end of 2021)



1 Medicines Landscape 2022/2023

MESSAGE FROM THE CHAIRMAN HE KUPU NĀ TE KAIHAUTŪ



It is with great pleasure, and few regrets that this is my final message from the Chairman.

Over the last five years, Medicines Am I happy with New Zealand has been able to ensure New Zealand?

that all players were reading from the same, scientifically prepared, hymn sheet. There is now a source of information, from which, stakeholders from patients to professors as commentators could make informed decisions.

New Zealand's Medicines Landscape has become a cornerstone, go-to reference for everyone from patient groups to Members of Parliament. This reference has proven to be the underpinning document in driving much of the lobbying for increases in funding for medicines over the years. The Landscape is supported by some of the best information, data, and commentary on medicines that New Zealand has ever seen.

Am I happy with where I leave medicines in New Zealand?

No, my ongoing call for a Medicines Strategy will continue both publicly and privately. If New Zealand cannot provide medicines to dying babies, or those only able to take it in fluids then we have serious ethical challenges ahead.


The road is long, and we have only travelled a short part of it.

Medicines New Zealand by the Numbers¹


Rongoā Aotearoa mā te Nama



Fast Facts – Medicines inequity for New Zealand patients He Meka Poto - Te tautika-kore ā-rongoā ka pā ki ngā tūroro o Aotearoa



Health inequities are avoidable, unnecessary, and unjust differences in the health of groups of people. To have equitable access to medicines means that everyone has a fair opportunity to obtain funded medicines to achieve their full health potential, and that no one is disadvantaged along the way. Having the right medicines at the right time will assure that our health system attains equity, quality, and efficiency. Currently, this is not the case.¹



The Cost of Ill Health


Te utu o te Māuiuitanga



In a 2010 study, direct and indirect COSts of ill health for one year were estimated to be up to \$12.9 billion or 8.5% of New Zealand GDP

- that study hasn't been repeated, so what could it be now?⁵

By failing to invest, New Zealand misses out on the savings to the health system and economic benefits that modern medicines offer.



How are New Zealanders doing? Key health priorities in New Zealand Kei te pēhea ngā tāngata o Aotearoa? Ngā take matua mō te hauora e mātāmua ana i Aotearoa



DIAB	ETES ^{4,8-11}
------	------------------------

Impacts our ethnic communities more significantly.

There are approximately 292,000 New Zealanders with diabetes including 26,000+ with type 1 diabetes

Nearly 40 people diagnosed every day

 1 in 8.5 Pacific Islanders

 ††††††††

 1 in 9.9 Indian

 †††††††††

 1 in 14.2 Māori

 †††††††††††

 1 in 33.2 European/other

 ††††††††

Between 2011 and 2020 New Zealand publicly funded none of the modern medicines for diabetes that were launched in the OECD during the decade.

In 2021, New Zealand publicly funded 3 modern medicines for diabetes – but only for a limited group of patients.

ARTHRITIS^{4,12}

Arthritis is a leading cause of disability and loss of wellbeing. Currently **670,000** people diagnosed with arthritis in New Zealand

Expected to rise to 1 million by 2040

In 2018, the economic value of lost wellbeing in New Zealand due to arthritis was estimated to be \$7.9 billion Māori men 1.4x more likely to have arthritis than non-Māori men



Arthritis affects people of all ages



Between 2011 and 2020, New Zealand publicly funded none of the modern medicines for arthritis that were launched in the OECD during the decade

COMPARED TO AUSTRALIA¹³

Comparisons with Australia for publicly funded modern medicines.

Australia publicly funds 105 modern medicines that New Zealand does not*

2 41 for cancer

4 for arthritis

10 for diabetes


4 for mental health 8 6 for

6 for rare disorders

*For medicines launched between 2011 and 2020

Access & Funding in Focus

Te arotahi ki te pūtea me te āheinga



THE FUNDING **GAP**⁸⁻¹⁰

There is a \$332 million investment gap in government funded medicines.

New Zealand's medicines budget has been significantly underfunded

Between 2007 and 2021. the community pharmaceutical component of the medicines budget shrank in real terms by 2.9%



\$65 investment per person per year is required to return medicines funding to the equivalent of 2007 levels

1.5 million patients

would benefit

if the medicines on

Pharmac's OFI

waiting list were


publicly funded.

5 years on average,

and are still waiting

for funding decision.

While the total health budget grew by 1% in real terms, the medicines budget has not kept up with population growth and inflation.



PHARMAC **REVIEW¹¹**

The final report on the independent review of Pharmac was released in 2022.

33 recommendations were made to the Minister of Health. If implemented, the recommendations will change the way Pharmac operates and makes decisions. The recommendations included;

Pharmac is to strengthen equity analysis in pharmaceutical assessment through the development of an integrated analytical framework.

In seeking the best health and equity outcomes Pharmac must work collaboratively with the Ministry

of Health. Health

New Zealand and

the Māori Health

Authority.



Ministry of Health to lead the development of a rare disorders strategy to coordinate efforts to address and improve the lives of people with rare disorders.

Accounting for – Pandemic preparedness & societal perspective Te kõrero i te take mõ - te noho takatū ki te mate urutā me ngā tirohanga a te hapori

PANDEMIC PREPAREDNESS¹

Globally, the pharmaceutical industry has recommended focusing on five priorities for pandemic preparedness. 1 Sustaining a thriving innovation ecosystem

2 Shaping a new social contract

3 Fostering sustainable manufacturing globally

Removing trade restrictions

5 Ensuring greater country readiness



Scan the QR code to read the expert opinion of **Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)**

SOCIETAL PERSPECTIVES²

New Zealand should be investing in prevention and treatment of disease to save the flow on effects downstream to patients, the healthcare system and wider economy. PHARMAC **excludes societal perspectives** from their health economic analysis when **considering whether to fund a medicine.** There are many other countries that do;



Countries that consider societal perspectives

- Australia
- Austria
- Estonia
- Lituania
- Latvia
- Canada
- Croatia
- Cuba
- England
- Germany
- Hungary
- Ireland


- Netherlands
- China
- Brazil
- Colombia
- Denmark
- India
- Indonesia
- Malaysia
- Argentina
- Paraguay
- Uruguay
- Poland

- Norway
- Philippines
- Portugal
- Scotland
- South Korea
- Spain
- Sweden
- Taiwan
- Thailand
- The United States
 of America

Where to from here? How does New Zealand catch up with peer nations? Ki hea atu i konei? Ka pēhea tā Aotearoa whai kia tū i te taha o ōna hoa ā-iwi i te ao?

Why should New Zealand have a rapid access scheme?

RAPID ACCESS TO MODERN MEDICINE



References

PAGES 1 - 2:

1. PhRMA. (April 2023). Global Access to New Medicines Report. Avaliable from: https://phrma.org/-/media/Project/PhRMA/ PhRMA-Org/PhRMA-Refresh/Report-PDFs/A-C/2023-04-06-PhRMA-Global-Access-to-New-Medicines-Report-FINAL.pdf

PAGES 3 - 4:

1. Medicines New Zealand. (2020). Members survey.

 NZIER. (May 2020). A new generation medicines policy. Wellington, New Zealand. Available from: https://www.medicinesnz. co.nz/fileadmin/user_upload/A_new_ generation_medicines_policy_-_FINAL.pdf
 New Zealand Public Health and Disability Act 2000 (Section 47). Available from: https://www.legislation.govt.nz/act/ public/2000/0091/latest/DLM80878.html [accessed 27 April 2023]

4. NZIER. (November 2022). Community pharmaceuticals: Expenditure trends. Wellington, New Zealand. Available from: https://www.medicinesnz.co.nz/fileadmin/ user_upload/Information_Leaflets/ community_pharmaceutical_expenditure_ nzier_to_medicines_nz_december_2018_ update_final.pdf

5. IQVIA. (2021). A Decade of Modern Medicines: An International Comparison 2011-2020. Available from: https:// www.medicinesnz.co.nz/fileadmin/ user_upload/IQVIA_Report_-_A_Decade_ of_Modern_Medicines_An_International_ Comparison_2011-2020__FINAL_.pdf
6. Medicines Australia. (2019). Comparison of access and reimbursement environments (COMPARE) 5th edition. Canberra, Australia. Available from: https://www. medicinesaustralia.com.au/wp-content/ uploads/sites/65/2020/11/MA_Comparefinal.pdf

 IQVIA. (2021). Access to Medicines (AtoM 3) 2011-2020. Available from: https://www. medicinesnz.co.nz/fileadmin/user_upload/ IQVIA_Access_to_Medicines_3_AtoM_3__ Report.pdf 8. PHARMAC. (2023). Application Tracker, Options for Investment list. Retrieved 07 March 2023 from: https://connect.pharmac. govt.nz/apptracker/s/ranking-lists-forfunding-applications?reportType=OFI

PAGES 5 - 6:

 PHARMAC. (2019). Achieving medicine access equity in Aotearoa New Zealand towards a theory of change. Available from: https://pharmac.govt.nz/assets/achievingmedicine-access-equity-in-aotearoa-newzealand-towards-a-theory-of-change.pdf
 Ministry of Health. COVID-19: Vaccine death. Available from: https://www.health. govt.nz/covid-19-novel-coronavirus/covid-19-data-and-statistics/covid-19-vaccinedata [Accessed 27 April 2023]

3. Ministry of Health. COVID-19: Current cases. Available from: https://www.health. govt.nz/covid-19-novel-coronavirus/covid-19-data-and-statistics/covid-19-currentcases [Accessed 27 April 2023]

4. Russell, L., et. al. (2022), Naā Kawekawe o Mate Korona. Impacts of COVID-19 in Aotearoa: Executive Summaries. Wellington, New Zealand. Available from: https://covidaotearoa.com/wp-content/ uploads/2023/01/Nga-Kawekawe-o-Mate-Korona-Executive-Summary-2023-01-24.pdf 5. Holt, H. (Nov 2010). New Zealand Treasury Working Paper 10/04: The Cost of Ill Health 6. New Zealand Treasury. CBAx Spreadsheet Model. (October 2022 model, value adjusted to 2023). Available from: https://www. treasury.govt.nz/publications/guide/cbaxspreadsheet-model [Accessed 27 Mar 2023] 7. NZIER. (2021). Transforming lives and saving money. The golden opportunity of kidney transplants and the system changes needed to lift the numbers. Wellington, New Zealand. Available from: https://www. nzier.org.nz/hubfs/Public%20Publications/ Client%20reports/transformina lives and saving money final report 5 november 2021.pdf

8. PWC (2021). The Economic and Social Cost of Type 2 Diabetes. Wellington, New Zealand. **9.** Coppell, K.J., Drabble, S.J., et al. (25 October 2019). The cost of diabetes-related hospital care to the Southern District Health Board in 2016/2017. New Zealand Medical Journal. Avaliable from: https:// assets-global.website-filescom/5e332a62 c703f653182faf47/5e332a62c703f639ff2fc cd6_Coppell%20FINAL.pdf.

10. Lichtenberg, F. (2017). The impact of pharmaceutical innovation on the longevity and Hospitalization of New Zealand cancer patients, 1998-2012. (2016) NBER Working Paper. Cambridge, Massachusetts, USA.

PAGES 7 - 8:

 Breast Cancer Foundation NZ. (2018).
 "I'm still here": Insights into living - and dying - with Advanced Breast Cancer in New Zealand. Wellington, New Zealand.
 Caswell-Jin, J.L. et al. (October 2018).
 Change in Survival in Metastatic Breast
 Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI cancer spectrum, 2(4), pky062. https://doi. org/10.1093/jncics/pky062.

3. Ministry of Health. Wai 2575 Māori Health Trends Report data and resources. Available from: https://www.health.govt.nz/our-work/ populations/maori-health/wai-2575-healthservices-and-outcomes-kaupapa-inquiry/ wai-2575-maori-health-trends-report-dataand-resources [Accessed 27 April 2023]

4. IQVIA. (2021). A Decade of Modern Medicines: An International Comparison 2011-2020. Available from: https:// www.medicinesnz.co.nz/fileadmin/ user_upload/IQVIA_Report_-_A_Decade_ of_Modern_Medicines_An_International_ Comparison 2011-2020 FINAL .pdf 5. Office of the Chief Coroner of New Zealand. (2022). Media Release. Avaliable from: https://coronialservices. iustice.aovt.nz/assets/Media-release-Deputy-Chief-Coroner-251022.pdf 6. Rare Disorders NZ. (2020). Fair for Rare. Call for National Framework for rare disorders in New Zealand, New Zealand, Available from: https://raredisorders.org.nz/ assets/4727 Rare-Disorders Fair-for-Rare-Reprint-21_FINAL_spreads.pdf

 HealthiNZ. (February 2022). Whitepaper: Impact of Living with a Rare Disorder in Aotearoa New Zealand. Available from: https://www.medicinesnz.co.nz/fileadmin/ user_upload/VOICE-OF-RARE-DISORDERS-White-Paper-February-2021-FINAL.pdf
 Health Quality & Safety Commission New Zealand. (December 2020). Diabetes. Available from: https://www.hqsc.govt.nz/ our-data/atlas-of-healthcare-variation/ diabetes/ [Accessed 27 April 2023].

9. Diabetes New Zealand. (9 August 2018). Beyond Type 1 x Diabetes NZ - The Kiwis Are Taking Over! Available from: https://www.diabetes.org.nz/news-andupdate/2018/8/9/beyond-type-1-x-diabetesnz-the-kiwis-are-taking-over?rq=26%2C000 [Accessed 27 April 2023]

10. *Ministry of Health. (2015). Living Well with Diabetes: A plan for people at high risk of or living with diabetes, 2015-2020. Wellington, New Zealand.*

11. PHARMAC. (21 December 2021). Media Release: PHARMAC to fund new diabetes medicines with amended Special Authority criteria. Available from: https:// pharmac.govt.nz/news-and-resources/ news/pharmac-to-fund-new-diabetesmedicines-with-amended-specialauthority-criteria/#:~:text=PHARMAC%20 has%20approved%20funding%20 for,Zealanders%20with%20type%20 2%20diabetes.&text=People%20with%20 high%2Drisk%20type,metformin)%20 from%201%20February%202021 [Accessed 28 March 2022].

12. Arthritis New Zealand (August 2018). The economic cost of arthritis in New Zealand in 2018. Wellington, New Zealand.
13. IQVIA. (2021). Access to Medicines (AtoM 3) 2011-2020. Available from: https://www. medicinesnz.co.nz/fileadmin/user_upload/ IQVIA_Access_to_Medicines_3_AtoM_3_ Report.pdf

PAGES 9 - 10:

1. OECD Statistics [Internet]: Available from: https://stats.oecd.org/ [Accessed 27 April 2023]

 2. OECD Health Division [Personal Communication, 19 Aug 2021].
 3. OECD Data [Internet]: Available from: https://data.oecd.org/conversion/ purchasing-power-parities-ppp.htm [Accessed 27 April 2023]

4. PHARMAC. (2019). Annual Report 2018-2019, For the year ended 30 Jun 2019. Available from: https://pharmac.govt.nz/ assets/annual-report-2018-2019.pdf **5.** Stats NZ (2019). National population estimates: At 30 June 2019. Available from https://www.stats.govt.nz/informationreleases/national-population-estimates-at-30-june-2019#

6. IMF World Economic Outlook Database [Internet]: Available from: https://www. imf.org/en/Publications/WEO/weodatabase/2018/October/download-entiredatabase [Accessed 27 April 2023] 7. IOVIA. (2021). A Decade of Modern Medicines: An International Comparison 2011-2020. Available from: https:// www.medicinesnz.co.nz/fileadmin/ user upload/IQVIA Report - A Decade of Modern Medicines An International Comparison 2011-2020 FINAL .pdf 8. NZIER. (November 2022). Community pharmaceuticals: Expenditure trends. Wellington, New Zealand. Avaliable from: https://www.nzier.org.nz/hubfs/Public%20 Publications/Reports/CPB%20Final%20 Report%2016%20November%202022.pdf 9. PHARMAC. (27 April 2021). Official Information Act Response. Avaliable from: https://pharmac.govt.nz/newsand-resources/official-information-act/ official-information-act-responses/ medicines-on-pharmacs-rankinglist/?keyword=options&page=1

 PHARMAC. (2023).Application Tracker, Options for Investment list. Retrieved 07 March 2023 from: https://connect.pharmac. govt.nz/apptracker/s/ranking-lists-forfunding-applications?reportType=OFI
 PHARMAC Review Panel. (2022). PHARMAC Review: Final report. Wellington: Ministry of Health. Avaliable from: https:// www.health.govt.nz/system/files/ documents/publications/pharmac-reviewfinal-report.pdf

PAGES 11 - 12:

1. IFPMA. (16 February 2023). Five priorities for futrue pandemic preparedness and response. Avaliable from: https://ifpma.org/ insights/five-priorities-for-future-pandemicpreparedness-and-response/ 2. Avsar, T.S., Yang, X. & Lorgelly, P. (2023) How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe. PharmacoEconomics. Avaliable from: https://doi.org/10.1007/s40273-022-01221-y 3. NZIER. (December 2019). Rapid access to new medicines in New Zealand. Wellinaton. New Zealand. Available from: https://www. medicinesnz.co.nz/fileadmin/user upload/ Medicines_New_Zealand_Rapid_Access_ to_New_Medicines_Dec_2019_Final.pdf 4. NZIER. (May 2020). A new generation medicines policy. Wellington, New Zealand. Available from: https://www.medicinesnz. co.nz/fileadmin/user_upload/A_new generation_medicines_policy_-_FINAL.pdf





Better health outcomes for New Zealanders info@medicinesnz.co.nz. +64.4.499.4277. www.medicinesnz.co.nz ISSN 2744-5941 (Print) ISSN 2624-3059 (Online) © Medicines New Zealand 2023